#USA #New York #Class Action #Rocket Pharmaceuticals #RCKT

Rocket Pharmaceuticals Investors Urged to Join Class Action Lawsuit

Overview

In a significant development for investors in Rocket Pharmaceuticals, LLC, a nationally renowned law firm, Bronstein, Gewirtz & Grossman, LLC, has announced the opportunity for investors who suffered substantial losses to lead a class action lawsuit against the company. This action follows the company's alarming disclosure regarding the safety of its clinical trials and the subsequent plummet in stock prices.

Class Action Details

The class action notification applies to all individuals and entities who bought or acquired Rocket securities between February 27, 2025, and May 26, 2025. The lawsuit aims to recover damages stemming from alleged violations of federal securities laws during this time frame. Investors who believe they are affected can participate by visiting bgandg.com/RCKT.

Reasons for the Lawsuit

The situation escalated when Rocket Pharmaceuticals disclosed that the FDA had imposed a clinical hold on its RP-A501 Phase 2 pivotal study on May 27, 2025. This hold was triggered by an incident involving a patient suffering from a Serious Adverse Event (SAE), a situation that ultimately led to death while that individual was enrolled in the trial. The grave concern arises from the fact that Rocket did not initially inform investors about a substantive amendment to the study's protocol, which was crucial information that could have impacted shareholder investment decisions.

According to the complaint, Rocket’s executives made overly optimistic statements about the project’s safety and progress. Simultaneously, they allegedly concealed material adverse facts about the safety and protocol of the RP-A501 clinical trial. Notably, the firm is accused of failing to communicate the risks associated with Serious Adverse Events (SAEs), including the risk of participant death during the study, which they had amended to introduce a new immunomodulatory agent without informing shareholders.

This combination of misleading statements and concealing significant details caused many investors to buy Rocket's securities at inflated prices, resulting in substantial financial losses when the truth surfaced. Following the announcement, the stock price fell dramatically from a closing market price of $6.27 per share on May 23, 2025, plummeting to $2.33 per share just four days later, marking a staggering decline of approximately 37% in a single trading day.

Next Steps

A class action lawsuit has already been initiated, and investors who have suffered losses are encouraged to review the details of the complaint available on bgandg.com/RCKT. For those interested in participating, the deadline to request that the court appoint them as lead plaintiff is August 11, 2025. It's crucial to note that investors can still recover losses even if they do not serve as lead plaintiffs.

No Financial Risk

Bronstein, Gewirtz & Grossman represents investors on a contingency fee basis, meaning there is no upfront cost. The firm will only recover legal fees and expenses if they achieve a successful outcome, offering a risk-free way for investors to seek justice.

The Firm’s Credentials

Bronstein, Gewirtz & Grossman, LLC has earned recognition for its work in securities fraud class actions and shareholder derivative suits, previously recovering hundreds of millions of dollars for investors nationwide. Their commitment to advocating for investors underscores their reputation as a leader in this field.

For ongoing updates and further information, interested parties can follow the firm on LinkedIn, X, Facebook, or Instagram. Attorney advertising is remarked, and prior outcomes do not guarantee similar future results.

Conclusion

In conclusion, Rocket Pharmaceuticals investors who believe they have been wronged have the opportunity to take action and potentially recover their losses through this class action lawsuit. The implications of the FDA’s hold and the revelations surrounding the clinical study reflect a broader concern about transparency and accountability in pharmaceutical companies. Investors are encouraged to act promptly to secure their claims and restore some of their investment losses.

Contact Information

For more details about joining the class action lawsuit or seeking guidance, investors can reach out to Peretz Bronstein, Esq., or Nathan Miller at Bronstein, Gewirtz & Grossman, LLC, via phone at 332-239-2660 or through the website.